A Coup for Gen-Probe
Executive SummaryChiron and Gen-Probe have entered into a strategic alliance which gives Chiron access to Gen-Probe's nucleic acid technologies and Gen-Probe gets rights to use HCV and other proprietary Chiron technology in manufacturing assays. Chiron will be selling Gen-Probe instruments to blood banks and clinical labs. Blood banks are starting to get interested in DNA screening for some major viral infections like HIV and HCV, because the technique is more sensitive and specific. The deal is a coup for Gen-Probe, because it gets rights to one of most coveted patents in diagnostics and it broadens Chiron's DNA platform beyond the disappointing bDNA.
You may also be interested in...
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.
Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.